wintergreen-flavored format makes these easy to take, potentially allowing for quicker absorption compared to traditional ...

Hims & Hers is shifting towards personalized medicine with AI-backed solutions. Find out why HIMS stock is buyable despite ...

Hims Hard Mints offers a chewable ED treatment that’s easy to use, stores in a discreet mint tin, and features a refreshing wintergreen flavor. Hard Mints are compounded medications that are ...

Hims & Hers Health stock plummeted after an FDA decision that prevents the company from selling compounded semaglutide. The company still expects to deliver strong revenue growth, though, and ...

Hims & Hers is shutting down the dermatology business it acquired in 2021, BI has learned. It said it's closing the skincare site Apostrophe to centralize its teledermatology offerings. Hims ...

Telehealth personalized care company Hims & Hers shuttered a central part of its dermatology offering, skincare brand Apostrophe, to "simplify" its dermatology offerings and operations ...

Hims & Hers Health, Inc. operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company ...

Hims & Hers Health (HIMS) stock enjoyed a 10% jump in price last week on news that the company plans to continue offering compounded versions of Ozempic and Wegovy. This approach is in response to ...

Hims & Hers Health (NYSE:HIMS) has taken investors on a wild ride in 2025. The stock surged nearly 200% earlier this year, reaching an all-time high by late February – only to plunge by half in ...

Apostrophe, a skin care telehealth brand headquartered in the Bay Area, is shutting down after almost four years under the Hims & Hers corporate umbrella. The skin care company, founded in ...